Sodium-glucose cotransporter 2 (SGLT2) inhibitors act to promote urinary glucose excretion and not only treat DM but also reduce inflammation, Na+/H+-exchange, and hyperuricemia. The gene discussed is SLC5A2; the disease is diabetes mellitus.